Drugs / PUL-042
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03097796 | Dec 2024 → Mar 2026 | disease related to hematopoietic stem cell transplant, hematologic disorder | Pulmotect, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT02566252 | Jul 2015 → Jan 2016 | — | Pulmotect, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06665100 | Jun 2025 → Apr 2027 expected | hematopoietic and lymphoid system neoplasm | Pulmotect, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04312997 | Jun 2020 → Jul 2021 | COVID-19 | Pulmotect, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04313023 | Jun 2020 → Jul 2021 | COVID-19 | Pulmotect, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03794557 | Jan 2019 → Dec 2020 | chronic obstructive pulmonary disease | Pulmotect, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PUL 042 | “The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung...” NCT06665100 ↗ |
| Modality | Oligonucleotide (other) | “20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution” NCT04313023 ↗ |
| Route | Inhaled | “PUL-042 Inhalation Solution” NCT02566252 ↗ |